Sorrento Therapeutics Inc (SRNE)

[Opti Mist]

Looking Ahead At Catalysts – Sorrento Therapeutics (SRNE)
Aug. 1, 2018 8:01 PM ET|

Summary

After years of acquisitions, preclinical research and early JV’s, SRNE is now advancing multiple clinical programs (e.g. CAR-T therapies, advanced analgesics) and is set to enter its next growth phase.

With the clinical programs underway, CEO Henry Ji is focusing efforts on funding, with options that range from dual-listing on the SEHK in China to more substantial partnerships.

SRNE is primed for growth. It’s undervalued relative to its most conservative analyst price target of $10 and has notable upside on delivery of multiple catalysts in the next 3-9 months.

https://seekingalpha.com/instablog/47373598-c-capital-research/5194677-looking-ahead-catalysts-sorrento-therapeutics-srne

Opti